289 related articles for article (PubMed ID: 36070054)
1. ALKBH5 inhibits thyroid cancer progression by promoting ferroptosis through TIAM1-Nrf2/HO-1 axis.
Li W; Huang G; Wei J; Cao H; Jiang G
Mol Cell Biochem; 2023 Apr; 478(4):729-741. PubMed ID: 36070054
[TBL] [Abstract][Full Text] [Related]
2. ALKBH5 decreases SLC7A11 expression by erasing m6A modification and promotes the ferroptosis of colorectal cancer cells.
Luo J; Yu H; Yuan Z; Ye T; Hu B
Clin Transl Oncol; 2023 Jul; 25(7):2265-2276. PubMed ID: 36820954
[TBL] [Abstract][Full Text] [Related]
3. High expression of AlkB homolog 5 suppresses the progression of non-small cell lung cancer by facilitating ferroptosis through m6A demethylation of SLC7A11.
Huang Z; Lin G; Hong Y; Weng L; Zhu K; Zhuang W
Environ Toxicol; 2024 Apr; ():. PubMed ID: 38642004
[TBL] [Abstract][Full Text] [Related]
4. RNA demethylase ALKBH5 regulates hypopharyngeal squamous cell carcinoma ferroptosis by posttranscriptionally activating NFE2L2/NRF2 in an m
Ye J; Chen X; Jiang X; Dong Z; Hu S; Xiao M
J Clin Lab Anal; 2022 Jul; 36(7):e24514. PubMed ID: 35689537
[TBL] [Abstract][Full Text] [Related]
5. Polyphyllin I induced ferroptosis to suppress the progression of hepatocellular carcinoma through activation of the mitochondrial dysfunction via Nrf2/HO-1/GPX4 axis.
Yang R; Gao W; Wang Z; Jian H; Peng L; Yu X; Xue P; Peng W; Li K; Zeng P
Phytomedicine; 2024 Jan; 122():155135. PubMed ID: 37856990
[TBL] [Abstract][Full Text] [Related]
6.
Zhao X; Zhao Z; Xie H; Gao W; Ye C
Discov Med; 2024 Jan; 36(180):61-70. PubMed ID: 38273746
[TBL] [Abstract][Full Text] [Related]
7. ALKBH5 activates FAK signaling through m6A demethylation in
Sun R; Yuan L; Jiang Y; Wan Y; Ma X; Yang J; Sun G; Zhou S; Wang H; Qiu J; Zhang L; Cheng W
Theranostics; 2023; 13(2):833-848. PubMed ID: 36632222
[No Abstract] [Full Text] [Related]
8. The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma.
Jin S; Li M; Chang H; Wang R; Zhang Z; Zhang J; He Y; Ma H
Mol Cancer; 2022 Apr; 21(1):97. PubMed ID: 35395767
[TBL] [Abstract][Full Text] [Related]
9. ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner.
Yang Z; Cai Z; Yang C; Luo Z; Bao X
EBioMedicine; 2022 Jun; 80():104019. PubMed ID: 35490460
[TBL] [Abstract][Full Text] [Related]
10. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner.
Guo X; Li K; Jiang W; Hu Y; Xiao W; Huang Y; Feng Y; Pan Q; Wan R
Mol Cancer; 2020 May; 19(1):91. PubMed ID: 32429928
[TBL] [Abstract][Full Text] [Related]
11. Maresin-1 inhibits high glucose induced ferroptosis in ARPE-19 cells by activating the Nrf2/HO-1/GPX4 pathway.
Li Y; Liu J; Ma X; Bai X
BMC Ophthalmol; 2023 Sep; 23(1):368. PubMed ID: 37674121
[TBL] [Abstract][Full Text] [Related]
12. RNA demethylase ALKBH5 promotes colorectal cancer progression by posttranscriptional activation of RAB5A in an m6A-YTHDF2-dependent manner.
Shen D; Lin J; Xie Y; Zhuang Z; Xu G; Peng S; Tang G; Bai L; Zhu M; Zhang Y; Huang Z; Wang P; Liu X; Huang M; Luo Y; Wang X; Yu H
Clin Transl Med; 2023 May; 13(5):e1279. PubMed ID: 37203239
[TBL] [Abstract][Full Text] [Related]
13. Demethylase ALKBH5 suppresses invasion of gastric cancer via PKMYT1 m6A modification.
Hu Y; Gong C; Li Z; Liu J; Chen Y; Huang Y; Luo Q; Wang S; Hou Y; Yang S; Xiao Y
Mol Cancer; 2022 Feb; 21(1):34. PubMed ID: 35114989
[TBL] [Abstract][Full Text] [Related]
14. ALKBH5 promotes the progression of infantile hemangioma through regulating the NEAT1/miR-378b/FOSL1 axis.
Peng K; Xia RP; Zhao F; Xiao Y; Ma TD; Li M; Feng Y; Zhou CG
Mol Cell Biochem; 2022 May; 477(5):1527-1540. PubMed ID: 35182329
[TBL] [Abstract][Full Text] [Related]
15. N6-methyladenosine demethylase ALKBH5 suppresses colorectal cancer progression potentially by decreasing PHF20 mRNA methylation.
Zhang Z; Wang L; Zhao L; Wang Q; Yang C; Zhang M; Wang B; Jiang K; Ye Y; Wang S; Shen Z
Clin Transl Med; 2022 Aug; 12(8):e940. PubMed ID: 35979628
[TBL] [Abstract][Full Text] [Related]
16. Down-regulated FTO and ALKBH5 co-operatively activates FOXO signaling through m6A methylation modification in HK2 mRNA mediated by IGF2BP2 to enhance glycolysis in colorectal cancer.
Ye M; Chen J; Lu F; Zhao M; Wu S; Hu C; Yu P; Kan J; Bai J; Tian Y; Tang Q
Cell Biosci; 2023 Aug; 13(1):148. PubMed ID: 37580808
[TBL] [Abstract][Full Text] [Related]
17. Bioactive peptide inhibits acute myeloid leukemia cell proliferation by downregulating ALKBH5-mediated m
Zhang L; Su X
Cell Oncol (Dordr); 2022 Jun; 45(3):355-365. PubMed ID: 35579750
[TBL] [Abstract][Full Text] [Related]
18. The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma.
Liu L; He J; Sun G; Huang N; Bian Z; Xu C; Zhang Y; Cui Z; Xu W; Sun F; Zhuang C; Man Q; Gu S
Clin Transl Med; 2022 May; 12(5):e778. PubMed ID: 35522946
[TBL] [Abstract][Full Text] [Related]
19. ALKBH5 promotes the proliferation of renal cell carcinoma by regulating AURKB expression in an m
Zhang X; Wang F; Wang Z; Yang X; Yu H; Si S; Lu J; Zhou Z; Lu Q; Wang Z; Yang H
Ann Transl Med; 2020 May; 8(10):646. PubMed ID: 32566583
[TBL] [Abstract][Full Text] [Related]
20. ALKBH5 inhibits the SIRT3/ACC1 axis to regulate fatty acid metabolism via an m6A-IGF2BP1-dependent manner in cervical squamous cell carcinoma.
Zhen L; Pan W
Clin Exp Pharmacol Physiol; 2023 May; 50(5):380-392. PubMed ID: 36705046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
